Abstract:Xiao Luo, 1, 2, * Zhangya He, 1, 3, * Xiaomin Sun, 1, 3 Xinqian Gu, 1, 3 Wanyu Zhang, 1, 3 Jiayi Gao, 1, 3 Xiaomin Li, 1, 3 Ru Jia, 4 Junxiang Wei, 5 Yan Yu, 1, 3 Xiaoqin Luo 1, 3 1 Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 2 Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, People's Republic of China; 3 Nutrition and Food Safety Engineering Research Center of Shaanxi Province, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 4 Department of Prosthodontics, Stomatological Hospital, College of Stomatology, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China; 5 Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China *These authors contributed equally to this work Correspondence: Xiaoqin Luo Department of Nutrition and Food Safety, School of Public Health, Xi'an Jiaotong University, Xi'an 710061, People's Republic of China Tel/Fax +86-29-82655111 Email luoxiaoqin2012@mail.xjtu.edu.cn Aim: Docosahexaenoic acid (DHA; C22; n-3) shows beneficial effects on Non-alcoholic fatty liver disease (NAFLD). Deacetylase Sirtuin1 (Sirt1) was reported to increase energy metabolism and decrease lipogenesis. Here, we investigated whether DHA plays a role in protecting against hepatic steatosis via Sirt1. Main Methods: Both in vivo and in vitro hepatic steatosis models were used: diet-induced obesity (DIO) model (middle-aged C57BL/6 mice fed a high-fat diet (HFD)) and palmitic acid (PA)-induced lipid accumulation cell model (HepG2 cells). Key Findings: In DIO mice, treatment with DHA (gavage supplementation) for 8 weeks not only inhibited the lipid accumulation, but also increased fatty acids (FA) oxidation and induced triglyceride export in liver. These changes were accompanied by attenuation of inflammation. Moreover, DHA reversed the HFD-induced reduction of Sirt1 in liver. Interestingly, the beneficial effects of DHA were reversed by lentivirus-mediated Sirt1 knockdown, accompanied with increased expression of markers of lipogenesis, inflammation and reduced FA oxidation. In HepG2 cells, DHA prevented the accumulation of PA-induced lipid droplets, the decrease of FA oxidation and the reduction of Sirt1 level. Inhibition of Sirt1 by sirtinol partially reversed the beneficial effects of DHA on PA-treated cells. Significance: DHA alleviated hepatic steatosis and reduced inflammation of liver in obese middle-aged mice by mechanisms involving Sirt1 activation. Keywords: non-alcoholic fatty liver disease, steatosis, docosahexaenoic acid, high-fat diet, Sirt1

Docosahexaenoic Acid Modulates Nonalcoholic Fatty Liver Disease by Suppressing Endocannabinoid System.

N-3 Polyunsaturated Fatty Acids in Phospholipid or Triacylglycerol Form Attenuate Nonalcoholic Fatty Liver Disease Via Mediating Cannabinoid Receptor 1/adiponectin/ceramide Pathway.

Differential Anti-Adipogenic Effects of Eicosapentaenoic and Docosahexaenoic Acids in Obesity.

DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model

Fatty Acid and Non-Alcoholic Fatty Liver Disease: Meta-analyses of Case-Control and Randomized Controlled Trials.

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Eicosapentaenoic and Docosahexaenoic Acids Differentially Alter Gut Microbiome and Reverse High-Fat Diet-Induced Insulin Resistance.

Long-Term Dietary Epa or Dha Supplementation Do Not Ameliorate Obesity but Improve Glucose Homeostasis Via Gut-Adipose Axis in Already Obese Mice

Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells

Effects of Dietary Supplementation of Fish Oil Plus Vitamin D3 on Gut Microbiota and Fecal Metabolites, and Their Correlation with Nonalcoholic Fatty Liver Disease Risk Factors: a Randomized Controlled Trial

DHA prevents altered 5-HT1A, 5-HT2A, CB1 and GABAA receptor binding densities in the brain of male rats fed a high-saturated-fat diet.

Dietary docosahexaenoic acid (DHA) downregulates liver DHA synthesis by inhibiting eicosapentaenoic acid elongation

Docosahexaenoic Acid-Rich Fish Oil Alleviates Hepatic Steatosis in Association with Regulation of Gut Microbiome in Ob/ob Mice.

Elevated Serum Phosphatidylcholine (16:1/22:6) Levels Promoted by Fish Oil and Vitamin D3 Are Highly Correlated with Biomarkers of Non-Alcoholic Fatty Liver Disease in Chinese Subjects.

A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice

Docosahexaenoic Acid Ameliorates Fructose-Induced Hepatic Steatosis Involving ER Stress Response in Primary Mouse Hepatocytes

Docosahexaenoic Acid Lessens Hepatic Lipid Accumulation and Inflammation Via the AMP-activated Protein Kinase and Endoplasmic Reticulum Stress Signaling Pathways in Grass Carp (ctenopharyngodon Idella)

Docosahexaenoic acid antagonizes the boosting effect of palmitic acid on LPS inflammatory signaling by inhibiting gene transcription and ceramide synthesis

Dietary docosahexaenoic acid reverses nonalcoholic steatohepatitis and fibrosis caused by conjugated linoleic acid supplementation in mice

Docosahexaenoic Acid (DHA) Alleviates Hepatic Lipid Accumulation by Regulating Mitochondrial Quality Control Through ERK Signaling Pathway in Grass Carp (ctenopharyngodon Idellus)

Eicosapentaenoic Acid-Enriched Phosphatidylcholine Attenuated Hepatic Steatosis Through Regulation of Cholesterol Metabolism in Rats with Nonalcoholic Fatty Liver Disease.